Six decisions, made with the evidence in hand.

Urchin integrated SharkTooth's proprietary RNA-seq data from CMT1A mouse models with a broad array of public evidence, and surfaced a drug class their scientific advisors had not originally prioritized.

Rather than narrowing to a single explanation, Urchin explored the space of mechanistic possibilities and returned four hypotheses, each with a rationale and suggested experiments. Reagents were ordered within a week.

Regulatory precedent, potency assay strategy and Phase 1-3 design, connected into a single evidence-based framework the advisor could share directly with the board and with KOLs.

A team that had spent years on the opportunity space wanted to know what was still hiding outside it. Several of the highest-priority results were candidates the scientific lead said he would not have identified independently.

Urchin synthesized evidence scattered across pharmacology, anatomy, physiology and comparative biology into biologically grounded estimates. It clarified which preclinical species were viable translational models, and resolved a mechanistic question that would otherwise have needed an experiment.

Urchin mapped where biological value comes from cohort scale versus per-patient depth, connected that to partner demand and market comparables, and turned an open-ended strategic debate into a concrete, depth-first investment decision.